We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Wearable Microneedle Patch Monitors Antibiotic Levels in Real Time

By LabMedica International staff writers
Posted on 15 Jul 2026

Therapeutic drug monitoring for agents with narrow therapeutic windows often relies on intermittent blood draws and laboratory analysis, providing only snapshots of exposure. More...

Real-time, minimally invasive tools could give clinicians clearer insight into pharmacokinetics over hours rather than moments. Antibiotic dosing, such as with vancomycin, is a frequent target for individualized monitoring. A new study shows a lightweight wearable microneedle patch can continuously track subcutaneous antibiotic levels and transmit results to a smartphone. 

Researchers at King Abdullah University of Science and Technology (KAUST; Thuwal, Saudi Arabia) developed an aptamer-based microneedle sensing platform integrated into a 6.7-gram wearable patch. The system combines microneedle access to interstitial fluid with electrochemical biosensing, onboard electronics, wireless communication, and smartphone visualization. It is designed to move dose assessment from periodic sampling toward continuous, real-time measurement.

The patch employs an array of tiny microneedles that reach interstitial fluid just beneath the skin, enabling continuous quantification of drug concentrations. Miniaturized electronics process the signals and transmit data via Bluetooth for real-time display on a mobile device. All sensing and telemetry components are integrated into a single, lightweight format suitable for on-body use.

The technology was demonstrated using vancomycin as a model antibiotic because it must be maintained within a relatively narrow concentration range to remain safe and effective. In laboratory experiments and preclinical studies, the platform successfully tracked changes in drug levels over several hours, indicating feasibility for minimally invasive, continuous pharmacokinetic monitoring. Although tested with an antibiotic, the researchers note the sensing architecture could potentially be adapted for other medicines that require careful dose management.

The study, conducted at KAUST, was published in Device on June 18, 2026. The team stated that future work will focus on extending monitoring duration, improving long-term stability, and evaluating the platform across a broader range of applications.

“Wearable technologies have changed the way people monitor many aspects of their health, from physical activity to heart rate and sleep. This research explores whether future wearable devices could also help us understand how medicines behave inside the body. While the technology is still at an early stage, it demonstrates a new approach to monitoring therapies continuously rather than relying on occasional measurements,” said Khaled Nabil Salama, professor of electrical and computer engineering and bioengineering at KAUST and lead author of the study.

Related Links
KAUST

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.